Selected research
Industry Research
Axial Spondyloarthritis Drugs Industry Research Report 2026
Market perspective
The global Axial Spondyloarthritis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Axial Spondyloarthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Axial Spondyloarthritis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Axial Spondyloarthritis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Axial Spondyloarthritis Drugs include Johnson & Johnson, Novartis AG, Eli Lilly and Company, AstraZeneca Plc, UCB SA, Sun Pharma Advanced Research Company Ltd, Sandoz International GmbH and Panacea Biotec Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Axial Spondyloarthritis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Axial Spondyloarthritis Drugs Market by Company
Johnson & Johnson
Novartis AG
Eli Lilly and Company
AstraZeneca Plc
UCB SA
Sun Pharma Advanced Research Company Ltd
Sandoz International GmbH
Panacea Biotec Ltd
Axial Spondyloarthritis Drugs Segment by Type
Ixekizumab
Secukinumab
Certolizumab Pegol
Etanercept Biosimilar
Others
Axial Spondyloarthritis Drugs Segment by Application
Clinic
Hospital
Home Care
Axial Spondyloarthritis Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Axial Spondyloarthritis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Axial Spondyloarthritis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Axial Spondyloarthritis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Axial Spondyloarthritis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Axial Spondyloarthritis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Axial Spondyloarthritis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ixekizumab
- Secukinumab
- Certolizumab Pegol
- Etanercept Biosimilar
- Others
Applications
- Clinic
- Hospital
- Home Care
Companies covered
- Johnson & Johnson
- Novartis AG
- Eli Lilly and Company
- AstraZeneca Plc
- UCB SA
- Sun Pharma Advanced Research Company Ltd
- Sandoz International GmbH
- Panacea Biotec Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Axial Spondyloarthritis Drugs Market Size (2021-2032)
- 2.2.2 Global Axial Spondyloarthritis Drugs Sales (2021-2032)
- 2.2.3 Global Axial Spondyloarthritis Drugs Market Average Price (2021-2032)
- 2.3 Axial Spondyloarthritis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ixekizumab
- 2.3.3 Secukinumab
- 2.3.4 Certolizumab Pegol
- 2.3.5 Etanercept Biosimilar
- 2.3.6 Others
- 2.4 Axial Spondyloarthritis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Home Care
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Axial Spondyloarthritis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Axial Spondyloarthritis Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Axial Spondyloarthritis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Axial Spondyloarthritis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Axial Spondyloarthritis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Axial Spondyloarthritis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Axial Spondyloarthritis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Axial Spondyloarthritis Drugs, Established Date
- 3.9 Global Axial Spondyloarthritis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Axial Spondyloarthritis Drugs Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis AG
- 4.2.1 Novartis AG Company Information
- 4.2.2 Novartis AG Business Overview
- 4.2.3 Novartis AG Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis AG Axial Spondyloarthritis Drugs Product Portfolio
- 4.2.5 Novartis AG Recent Developments
- 4.3 Eli Lilly and Company
- 4.3.1 Eli Lilly and Company Company Information
- 4.3.2 Eli Lilly and Company Business Overview
- 4.3.3 Eli Lilly and Company Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly and Company Axial Spondyloarthritis Drugs Product Portfolio
- 4.3.5 Eli Lilly and Company Recent Developments
- 4.4 AstraZeneca Plc
- 4.4.1 AstraZeneca Plc Company Information
- 4.4.2 AstraZeneca Plc Business Overview
- 4.4.3 AstraZeneca Plc Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Plc Axial Spondyloarthritis Drugs Product Portfolio
- 4.4.5 AstraZeneca Plc Recent Developments
- 4.5 UCB SA
- 4.5.1 UCB SA Company Information
- 4.5.2 UCB SA Business Overview
- 4.5.3 UCB SA Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 UCB SA Axial Spondyloarthritis Drugs Product Portfolio
- 4.5.5 UCB SA Recent Developments
- 4.6 Sun Pharma Advanced Research Company Ltd
- 4.6.1 Sun Pharma Advanced Research Company Ltd Company Information
- 4.6.2 Sun Pharma Advanced Research Company Ltd Business Overview
- 4.6.3 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Product Portfolio
- 4.6.5 Sun Pharma Advanced Research Company Ltd Recent Developments
- 4.7 Sandoz International GmbH
- 4.7.1 Sandoz International GmbH Company Information
- 4.7.2 Sandoz International GmbH Business Overview
- 4.7.3 Sandoz International GmbH Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sandoz International GmbH Axial Spondyloarthritis Drugs Product Portfolio
- 4.7.5 Sandoz International GmbH Recent Developments
- 4.8 Panacea Biotec Ltd
- 4.8.1 Panacea Biotec Ltd Company Information
- 4.8.2 Panacea Biotec Ltd Business Overview
- 4.8.3 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Product Portfolio
- 4.8.5 Panacea Biotec Ltd Recent Developments
5 Global Axial Spondyloarthritis Drugs Market Scenario by Region
- 5.1 Global Axial Spondyloarthritis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Axial Spondyloarthritis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Axial Spondyloarthritis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Axial Spondyloarthritis Drugs Sales by Region: 2027-2032
- 5.3 Global Axial Spondyloarthritis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Axial Spondyloarthritis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Axial Spondyloarthritis Drugs Revenue by Region: 2027-2032
- 5.4 North America Axial Spondyloarthritis Drugs Market Facts & Figures by Country
- 5.4.1 North America Axial Spondyloarthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Axial Spondyloarthritis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Axial Spondyloarthritis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Axial Spondyloarthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Axial Spondyloarthritis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Axial Spondyloarthritis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Axial Spondyloarthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Axial Spondyloarthritis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Axial Spondyloarthritis Drugs Market Facts & Figures by Country
- 5.7.1 South America Axial Spondyloarthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Axial Spondyloarthritis Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Axial Spondyloarthritis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Axial Spondyloarthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Axial Spondyloarthritis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Axial Spondyloarthritis Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Axial Spondyloarthritis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Axial Spondyloarthritis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Axial Spondyloarthritis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Axial Spondyloarthritis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Axial Spondyloarthritis Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Axial Spondyloarthritis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Axial Spondyloarthritis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Axial Spondyloarthritis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Axial Spondyloarthritis Drugs Value Chain Analysis
- 8.1.1 Axial Spondyloarthritis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Axial Spondyloarthritis Drugs Production Mode & Process
- 8.2 Axial Spondyloarthritis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Axial Spondyloarthritis Drugs Distributors
- 8.2.3 Axial Spondyloarthritis Drugs Customers
9 Global Axial Spondyloarthritis Drugs Analyzing Market Dynamics
- 9.1 Axial Spondyloarthritis Drugs Industry Trends
- 9.2 Axial Spondyloarthritis Drugs Industry Drivers
- 9.3 Axial Spondyloarthritis Drugs Industry Opportunities and Challenges
- 9.4 Axial Spondyloarthritis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst